Skip to main content

Advertisement

Table 3 Association between KRAS genotypes and hepatoblastoma susceptibility after stratification by age, gender, and clinical stages

From: NRAS and KRAS polymorphisms are not associated with hepatoblastoma susceptibility in Chinese children

Variables rs12587 (patients/controls) AOR (95% CI)a P a rs7973450 (patients/controls) AOR (95% CI)a P a rs7312175 (patients/controls) AOR (95% CI)a P a Combined genotypes (patients/controls) AOR (95% CI)a P a
GG GT/TT AA AG/GG GG GA/AA 0 1–3
Age, months
 < 17 70/278 44/176 1.00 (0.66–1.53) 0.998 90/371 24/83 1.20 (0.72–2.00) 0.486 94/358 20/106 0.70 (0.41–1.19) 0.189 73/275 41/179 0.87 (0.57–1.33) 0.517
 ≥ 17 58/331 41/173 1.35 (0.87–2.10) 0.179 88/427 11/77 0.69 (0.35–1.36) 0.286 73/392 26/112 1.25 (0.76–2.04) 0.383 66/330 33/174 0.95 (0.60–1.50) 0.817
Gender
 Female 49/222 35/157 0.99 (0.61–1.60) 0.963 68/311 16/68 1.03 (0.56–1.90) 0.916 67/284 17/95 0.76 (0.42–1.35) 0.344 54/223 30/156 0.77 (0.47–1.26) 0.302
 Male 79/387 50/192 1.27 (0.86–1.89) 0.231 110/487 19/92 0.92 (0.54–1.57) 0.750 100/456 29/123 1.07 (0.68–1.70) 0.765 85/382 44/197 1.01 (0.67–1.50) 0.980
Clinical stages
 I + II 56/609 41/349 1.28 (0.84–1.97) 0.249 75/798 22/160 1.47 (0.89–2.44) 0.132 76/740 21/218 0.94 (0.57–1.56) 0.803 60/605 37/353 1.06 (0.69–1.64) 0.784
 III + IV 32/609 23/349 1.25 (0.72–2.17) 0.430 48/798 7/160 0.73 (0.32–1.64) 0.445 44/740 11/218 0.85 (0.43–1.67) 0.626 37/605 18/353 0.83 (0.47–1.48) 0.532
  1. AOR adjusted odds ratio, CI confidence interval
  2. aAdjusted for age and gender, with the stratification factor omitted